KRAS and cancer: We treated multiple NRAS (SKMEL-103, M245, and SKMEL-2), KRAS (AsPC1, PANC1, and SU.86.86), and HRAS (RH-36 and SMS-CTR) mutant cancer cell lines with different concentrations of BAY 11-7082 and measured cell viability.